All News Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
6.61 ^USD	+7.13%		-1.34%	-26.47%

May. 15	Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
May. 07	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Travere Therapeutics : Corporate Overview – May 2024	May. 16	PU
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 15	GL
Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM	May. 15
Travere Therapeutics : Equity Incentive Plan - Form 8-K	May. 13	PU
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress	May. 09	GL
Travere Therapeutics to Present at Upcoming Investor Conferences	May. 08	GL
Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	May. 07	MT
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Transcript : Travere Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Travere: Q1 Earnings Snapshot	May. 06	AQ
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M	May. 06	MT
Travere Therapeutics Reports First Quarter 2024 Financial Results	May. 06	GL
Travere Therapeutics to Report First Quarter 2024 Financial Results	Apr. 29	GL
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy	Apr. 25	AQ
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	Apr. 24	MT
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	Apr. 24	GL
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	Apr. 24	MT
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	Apr. 24	PR
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24	CI
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International	Apr. 04	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

All News

Filters